{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:28:34Z","timestamp":1762475314750,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jdcr.2021.10.004","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T22:05:23Z","timestamp":1634162723000},"page":"12-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Certolizumab pegol treatment for leg ulcers due to rheumatoid vasculitis"],"prefix":"10.1016","volume":"18","author":[{"given":"Maureen Tania","family":"Meling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akane","family":"Minagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuhei","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdcr.2021.10.004_bib1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/ard.57.2.114","article-title":"The diagnostic value of perivascular infiltrates in muscle biopsy specimens for the assessment of rheumatoid vasculitis","volume":"57","author":"Voskuyl","year":"1998","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jdcr.2021.10.004_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1067\/mjd.2001.111633","article-title":"Chronic venous insufficiency and venous leg ulceration","volume":"44","author":"Valencia","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2021.10.004_bib3","first-page":"54","article-title":"IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy","volume":"43","author":"Scott","year":"1981","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.jdcr.2021.10.004_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/ket326","article-title":"Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy","volume":"53","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.jdcr.2021.10.004_bib5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11926-010-0130-1","article-title":"Rheumatoid vasculitis: vanishing menace or target for new treatments?","volume":"12","author":"Bartels","year":"2010","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.jdcr.2021.10.004_bib6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11926-008-0072-z","article-title":"Vasculitis induced by tumor necrosis factor-targeted therapies","volume":"10","author":"Ramos-Casals","year":"2008","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"10.1016\/j.jdcr.2021.10.004_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4161\/mabs.2.2.11271","article-title":"Certolizumab pegol","volume":"2","author":"Goel","year":"2010","journal-title":"MAbs"},{"issue":"11","key":"10.1016\/j.jdcr.2021.10.004_bib8","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in\u00a0vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"1-2","key":"10.1016\/j.jdcr.2021.10.004_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jim.2009.06.009","article-title":"Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis","volume":"348","author":"Palframan","year":"2009","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.jdcr.2021.10.004_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13550-016-0245-0","article-title":"99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study","volume":"6","author":"Lambert","year":"2016","journal-title":"EJNMMI Res"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512621007220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512621007220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:23:36Z","timestamp":1762475016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512621007220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":10,"alternative-id":["S2352512621007220"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2021.10.004","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Certolizumab pegol treatment for leg ulcers due to rheumatoid vasculitis","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2021.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}